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ABSTRACT
Myocardial involvement with clinical symptoms is a rare manifestation of systemic lupus erythematosus (SLE), despite the 
relatively high prevalence of myocarditis at autopsies of SLE patients. In this review, we report the case of a 19-year-old male 
SLE patient who initially presented with myopericarditis and was successfully treated with high dose of glucocorticoids. 
(Korean Circ J 2011;41:334-337)
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 Introduction
Myocardial involvement is not uncommon in systemic lu-
pus erythematosus (SLE). Sometimes lupus myocarditis can 
be a life-threatening complication of SLE. But, SLE-related 
myopericarditis is very rare in a young male patient. 
We report a case of SLE-associated myopericarditis in a yo-
ung male without clear evidence of viral infection based on 
viral markers in blood. The patient’s cardiac function drama-
tically improved after treatment with steroids without any 
additional complications. 
Case
A 19-year-old male was admitted to the Combined Armed 
Forces Hospital with a 7-day history of fever, cough, dyspnea, 
orthopnea, and chest pain. Based on the chest radiograph and 
computed tomography, he was diagnosed with a pericardial 
effusion and pneumonia (Fig. 1A), and was transferred to our 
hospital for evaluation of the cause and treatment. His me-
dical and family histories were unremarkable. 
On examination, his blood pressure was 110/70 mmHg, pul-
se rate was 112 beats/min, respiratory rate was 24 breaths/min, 
and body temperature was 38°C. Jugular veins were engorg-
ed. On cardiac auscultation, the cardiac rhythm was regular 
and rapid, summation gallops were heard at the cardiac apex, 
and there were pericardial friction rubs along with left lower 
sternal border in the sitting position. Bilateral pretibial pitting 
edema was present on admission.
On admission, blood tests showed white blood cell count of 
5,420/mm
3, hemoglobin 10.6 g/dL and platelet count of 94,000/ 
mm
3. C-reactive protein was 4.59 mg/L (normal, 0-3 mg/L). 
The blood chemistry revealed blood urea nitrogen to be 24.0 
mg/dL, creatinine 1.1 mg/dL, total protein 5.7 g/dL, and albu-
min 2.6 g/dL. Quantitative analysis of proteinuria revealed 8.0 
g/day of proteinuria. 
He had hypoxemia due to ventilation-perfusion mismatch. 
The levels of cardiac markers were elevated; troponin-I 0.87 
ng/mL (normal, 0-0.05 ng/mL) and myoglobin 371 ng/dL (nor-
mal, 16.3-96.5 ng/dL). Sputum smear and polymerase chain 
reaction tests were negative for acid-fast bacillus. An electro-
cardiogram (ECG) revealed sinus tachycardia and diffuse T-
wave inversion in which leads (Fig. 2A). Echocardiography 
demonstrated severe left ventricular systolic dysfunction 
{left ventricular ejection fraction (LVEF) was 18%} with se-
vere global hypokinesia and preserved wall thickness (Fig. 
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mm anterior to the right ventricle, 18 mm around the right at-
rium and 2 mm posterior to the LV. There were no signs of car-
diac tamponade on both echocardiography and clinical find-
ings. At first, we suspected viral myopericarditis, and started 
conservative treatment for congestive heart failure and peri-
carditis. But, there was no improvement in LVEF as well as in 
the clinical findings. Viral markers for cytomegalovirus, Cox-
sackie virus B type 2, Herpes simplex virus, and Epstein-Barr 
virus were all negative. During conservative treatment, he com-
plained of new-onset ankle joint pain and tender erythema-
tous swellings in both the ankles. The immunofluorescence 
tests were positive for anti-nuclear antibody (1 : 640 titre), anti-
dsDNA antibodies (683.4 IU/mL), and anti-extractable nu-
clear antigen antibodies (anti-Sm, anti-RNP, anti-Ro, and an-
ti-La), and the complement level was low (Table 1). We con-
cluded that the patient had SLE according to the American 
Rheumatism Association/American College of Rheumatolo-
gy classification criteria for SLE. On the 13th day of admis-
sion, we started treatment with high-dose glucocorticoids 
(methylprednisolone 1,000 mg intravenously daily for three 
days followed by 1 mg/kg per day in divided doses). On fol-
low-up examination, ECG showed normalization of T-wave 
inversion (Fig. 2C) and echocardiography obtained just be-
fore discharge showed improved systolic function (Fig. 2D). 
A   B
Fig. 1. Chest X-ray. A: chest X-ray shows patchy consolidation with multiple nodular densities in both the lower lung fields and cardiomega-
ly. B: chest X-ray following treatment with steroids shows improving consolidation and cardiomegaly.
Fig. 2. Electrocardiogram and Echocardiogram. A: electorcardiogram (ECG) shows sinus tachycardia and diffuse T-wave inversion in which 
leads on the day of admission. B: parasternal short axis view shows pericardial effusion and decreased left ventricular ejection fraction. C: 
ECG shows normal sinus rhythm and left ventricular hypertrophy after glucocorticoid treatment. D: parasternal short axis views show im-
proving left ventricular ejection fraction and decreasing pericardial effusion after glucocorticoid treatment.
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Chest X-ray also showed improving consolidation in both 
the lung fields and cardiomegaly (Fig. 1B). Complement 3 
was normalized and anti-dsDNA antibodies decreased from 
683.4 IU/mL to 383.8 IU/mL (WHO u/mL, normal 0-93). He 
was discharged on the 33rd day of admission with oral pred-
nisolone, and he visited the outpatient department 1 month 
later. In this 1 month, he had no symptoms. Echocardiography 
revealed normal LVEF, without significant valvular disease 
and pericardial effusion compared to the last examination 
(Table 2). Subsequently, the steroid medication was tapered 
and it was planned to maintain him on SLE-specific treatment 
in the Rheumatologic department.
Discussion 
SLE is an autoimmune inflammatory disease of unknown 
etiology that affects various parts of the body, including all 
components of the cardiovascular system.
1) The prevalence 
of lupus ranges from approximately 40-150 cases per 100,000 
in the USA.
2) In adults, the female-to-male ratio is 7-15 : 1.
3)
Cardiac involvement in SLE may comprise of involvement 
of the pericardium, myocardium, endocardium, heart valves, 
and coronary or pulmonary arteries.
4)
Pericardial involvement is the most frequent cause of symp-
tomatic cardiac disease
5) and is the most common echocar-
diographic finding in SLE patients. The pericardium can be in-
volved by acute and chronic inflammatory changes; granular 
deposition of immunoglobulin and C3, demonstrated by di-
rect immunofluorescence,
6) supporting the role of immune 
complexes in the development of pericarditis.
Myocarditis is an uncommon, often asymptomatic mani-
festation of SLE with a prevalence of 8-25% in different stud-
ies.
7) Global hypokinesis may be an echocardiographic indi-
cation of myocarditis and is present in approximately 6% of 
SLE patients.
8) The gold standard for diagnosing myocarditis 
in SLE remains the endomyocardial biopsy.
9) However, an en-
domyocardial biopsy is invasive with procedure-related risks 
and the diagnostic yield is low in 10-20% of cases, so it is not 
powerful enough to confirm the diagnosis.
10) Lupus myocar-
ditis can be diagnosed based on clinical suspicion and echo-
cardiographic evidence of a reduced LVEF and segmental or 
global wall motion abnormality, once the other etiologies, such 
as viral and ischemic cardiomyopathy, have been excluded.
9)11)
Immunofluorescence studies demonstrate fine granular 
immune complexes and complement deposition in the walls 
and perivascular tissues of myocardial blood vessels, sup-
porting the hypothesis that lupus myocarditis is an immune 
complex-mediated disease. 
The treatment of lupus myopericarditis has not been as-
sessed in controlled trials. 
Lupus myocarditis, although mild, has to be treated im-
mediately with high-dose corticosteroids. In the most severe 
forms, it is necessary to use intravenous pulse corticosteroid 
therapy (methylprednisolone 1 g/day for three consecutive 
days) followed by high doses of oral prednisone. Immuno-
suppressants, namely cyclophosphamide or azathioprine, and 
intravenous IgG may be beneficial in the treatment of myocar-
ditis.
5) Early mechanical circulatory supports help to save the 
life and prevent multi-organ failures in patients with fulmi-
nant myocarditis.
12) 
In the present case, the patient was initially diagnosed with 
myopericarditis on the basis of his symptoms, diffuse T-wave 
Table 1.  Immunofluorescence tests
Investigation Value Normal range
Anti-double stranded DNA (WHO U/mL) 683.4 0-93
Complement 3 (mg/dL) <16.4 50-120
Complement 4 (mg/dL) <6.00 20-500
Lupus anticoagulant Negative Negative
Anti phospholipid IgM (MPL/mL) 002.2 0-10
Fluorescent antinuclear antibody test (titre) 1 : 640
p-anti-neutrophil cytoplasmic antibody Negative Negative
c-anti-neutrophil cytoplasmic antibody Negative Negative
Anti-Sjögren’s syndrome A (Ro) antibody (U/mL) 119.2 0-20
Anti-Sjögren’s syndrome B (La) antibody (U/mL) 098.7 0-20
Anti-Smith antibody (U/mL) 006.0 0-20
Anti-Smith/ribonucleoprotein antibody 023.3 0-20
Table 2. Serial echocardiographic findings 
HD#1 HD#10 HD#30
F/U after
 1 month
LVDd (mm) 64 68 62 58
LVDs (mm) 58 57 45 34
EF (%) 18 30 47 60
HD: hospital day, F/U: follow up, LVDd: left ventricular diastolic 
dimension, LVDs: left ventricular systolic dimension, EF: ejection 
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inversion on ECG, elevated cardiac markers and echocardio-
graphic findings. He was given conservative management 
with angiotensin-converting enzyme inhibitors and diuretics. 
However, there was no improvement in his symptoms and 
the common cardiotrophic viral markers were all negative. 
Also, the patient had pericarditis, thrombocytopenia and 
proteinuria. Because the previous typical clinical signs and 
the positive immunofluorescence tests were suitable for mak-
ing the diagnosis of SLE, we confirmed the diagnosis of myo-
pericaditis associated with SLE in this patient. After a provi-
sional diagnosis of myopericarditis with SLE was made, he 
was treated with intravenous corticosteroid pulse therapy (me-
thylprednisolone 1 g/day for three consecutive days) followed 
by high doses of oral prednisone. After 3 days of steroid ther-
apy, the patient’s signs and symptoms were stabilizing and 
echocardiographic findings were improved.
Initially, we had considered myopericarditis to be caused 
by viral infection; however, the final diagnosis was myoperi-
carditis during presentation of primary SLE based on the cli-
nical manifestations, echocardiography, immunofluorescence 
tests and good response to steroid therapy. Because the treat-
ment of SLE induced myopericarditis should be needed for 
some specific therapy such as corticosteroid, this case shows 
that careful investigation is needed for search of the cause of 
myopericarditis in a young male, and not only viral infec-
tion but also autoimmune disease should be investigated for. 
In this report, we described the first case of a Korean young 
male SLE patient in whom the first manifestation was of myo-
pericarditis and treatment with glucocorticoids resulted in a 
good clinical outcome.
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